DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT04920617)
A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
Who can join: Review the eligibility criteria below.
Location: Compassionate Cancer Care Medical Group — Fountain Valley, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (50 Sites)
Showing the first 25 of 50 sites.
- Compassionate Cancer Care Medical Group — Fountain Valley, California
- Boca Raton Regional Hospital — Boca Raton, Florida
- BRCR Medical Center Inc. — Hollywood, Florida
- BRCR Medical Center Inc. — Plantation, Florida
- Comprehensive Hematology and Oncology — St. Petersburg, Florida
- Blood and Marrow Transplant Group of Georgia — Atlanta, Georgia
- Indiana University Health Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
- Tulane Cancer Center Office of Clinical Research — New Orleans, Louisiana
- Oncology Hematology West, PC dba Nebraska Cancer Specialists — Omaha, Nebraska
- Christus St. Vincent Regional Cancer Center — Santa Fe, New Mexico
- Brody School of Medicine at East Carolina University — Greenville, North Carolina
- Gabrail Cancer Center Research — Canton, Ohio
- University of Toledo Medical Center — Toledo, Ohio
- Toledo Clinic Cancer Center — Toledo, Ohio
- Allegheny Health Network (AHN) West Penn Hospital — Pittsburgh, Pennsylvania
- Reading Hospital - McGlinn Cancer Institute — West Reading, Pennsylvania
- Prairie Lakes Health Care System — Watertown, South Dakota
- Royal Adelaide Hospital — Adelaide, South Australia
- Epworth Freemasons Hospital — Melbourne, Victoria
- Box Hill Hospital — Melbourne, Victoria
- Westmead Hospital — Westmead,
- Saskatoon Cancer Center — Saskatoon, Saskatchewan
- Hôpital Avicenne — Bobigny,
- Centre d'Oncologie de Gentilly — Nancy,
- Hôpital Privé du Confluent — Nantes,
📞 Contact the Study Coordinator
Phone: (714) 698-0300
Email: ericlee@compcancercare.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Relapsed Diffuse Large B-cell Lymphoma
Explore by condition: All Relapsed Diffuse Large B-cell Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.